Can ILR Reduce the Risk of Arm Lymphedema?
Status
Conditions
Treatments
Details and patient eligibility
About
Breast cancer-related lymphedema (BCRL) is a debilitating, usually lifelong burden for breast cancer survivors. For the breast cancer patients receiving axillary lymph node dissection (ALND), the likelihood of BCRL is about 20%. Lymphatico-venous anastomosis (LVA) has been accepted as a method of treating extremity lymphedema. A few studies have mentioned the prophylactic effect of LVA on BCRL. However, there is still lack of a large-scale randomized controlled trial to corroborate its efficacy. Therefore, the goal of this study is to conduct a prospective randomized controlled trial to evaluate if immediate lymphatic reconstruction (ILR) with LVA could have a clinically significant effect on the reduction of BCRL occurrence.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Female patients with unilateral breast cancer
- Going to receive axillary lymph node dissection, or sentinel lymph node biopsy but being highly suspected of axillary metastasis preoperatively
Exclusion criteria
- Had received axillary lymph node dissection
- Going to receive bilateral axillary lymph node dissections
- Already have arm lymphedema
- Allergy to the dye used intraoperatively
Trial design
Primary purpose
Allocation
Interventional model
Masking
240 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal